NFE2L2 and atherosclerosis: SFN inhibits key events in atherosclerosis development and progression through MAPK/AP-1/NF-κB [146] and Nrf2/ARE pathways and possibly the cPKCβII/Akt (Akt-protein kinase B) signal pathway [131].